Four Years Analysis of Cancer Genetic Clinics Activity in France from 1994 to 1997: A Survey on 801 Patients

Sobol, Hagay; Bignon, Yves‐Jean; Bonaïti, Catherine; Cuisenier, Jean; Lasset, Christine; Lortholary, Alain; Noguès, Catherine; Stoppa‐Lyonnet, Dominique; Eisinger, François

doi:10.1155/1999/140498

Cited by 14 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study was carried out on a national sample of French families selected throughout the country. In France there exist more than 32 CGC covering the whole country (Sobol et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families

et al. 2000

View full text Add to dashboard Cite

Due to the technical difficulties involved in identifying BRCA1/2 genetic mutations, the affected patients have to be investigated before testing can be made available to all the relatives at risk. Here, we studied the attendance rates at cancer genetic clinics (CGC) and the uptake of genetic testing in first/second degree relatives after the first BRCA1 mutated woman with cancer had been informed in the family. We carried out a survey on French cancer geneticists involved in breast/ovarian CGC, asking them to select their first three BRCA1 family records. Data collection was carried out retrospectively by telephone interview with a standardised closed item questionnaire. Considering only those families (n=37) where the index case had been informed for at least 8 months at the time of the survey, the overall attendance at CGC of first/second degree relatives (n=419) was 31.7% (n=133) and the overall uptake of BRCA1 testing was 26.7% (n=112). Among those who attended the CGC (n=133), 84.2% (n=112) requested genetic testing (95% confidence interval: 78–90.4%). Among the first degree relatives, the unaffected women who attended accounted for 59.8% and 51.2% requested testing after the index case had been informed. Women with cancer had a higher attendance rate (83.3%) than unaffected women (36.1%) (Odds Ratio (OR)=8.86; p<0.001) and first degree relatives (51.4%) than second degree relatives (17.9%) (OR=2.87; p<0.001); women (43%) also attended more frequently than men (16%) (OR=3.97, p<0.001). In French BRCA1 mutated families, female first degree relatives of the index patient show the most interest in genetic testing. Copyright © 2000 John Wiley & Sons, Ltd.

show abstract

“…This study was carried out on a national sample of French families selected throughout the country. In France there exist more than 32 CGC covering the whole country (Sobol et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Studies of cancer genetic services in France and the United Kingdom have shown that there is a large demand for such services, especially in the area of breast cancer genetics. [4][5][6] According to a survey of North American genetic counsellors, cancer genetics is among the top three most commonly cited specialty areas. 7 We estimate that there are approximately 4200 consultations conducted for breastovarian cancer each year in Ontario, or one for every 1400 women in the population.…”

Section: Discussionmentioning

confidence: 99%

Genetic counselling for familial breast and ovarian cancer in Ontario

Andermann

2002

Journal of Medical Genetics

View full text Add to dashboard Cite

“…A finding pointing to the presence of an increased cancer risk goes beyond the consultee's individual body, and means bad news for her entire family. Even when the consultee already suffers from cancer -this is the case in approximately half of the French consultations (Sobol et al, 1999) -the encounter will focus not on her present cancer but on the genetic risk this cancer may express -a risk that she shares with other members of her family, in particular her children. A consultee sitting in a cancer genetic clinic is not, thus, the only patient in the room.…”

Section: Assessing Family Riskmentioning

confidence: 99%

BRCA Patients and Clinical Collectives

Bourret¹

2005

Soc Stud Sci

View full text Add to dashboard Cite

Since the late 1980s, in France and in a number of other countries, cancer genetics testing has become a clinical reality, particularly for hereditary breast and ovarian cancer. BRCA tests allowing for the assessment of an increased cancer risk among patients and their healthy relatives are now being routinely performed as part of clinical practice. Based on fieldwork on French clinical cancer genetics and on the French Cancer Genetics Collaborative Network, this paper examines the configuration of entities, actors and activities mobilized by the performance of BRAC testing, and argues that the development of clinical molecular genetic practices is predicated upon the development of new forms of collaborative work that lead to a transformation of the content and organization of medical activities and judgements. The paper analyses three major collective configurations - local multidisciplinary collectives, data collectives and new clinical collectives - and argues that they not only provide the material conditions needed to carry out the relevant activities, but also articulate a series of distinctive bio-clinical interventions. These interventions provide an interface with research activities, produce the epidemiological measurements and tools that are a sine qua non for clinical work in this field, and, most importantly, establish the conventions that underlie practices, which define the criteria that turn tools and novel entities into operational components of clinical settings. It thus appears that in the field of clinical cancer genetics, bioclinical collectives, as a locus of expertise, have replaced the individual judgement of the practicing clinician.

show abstract

Four Years Analysis of Cancer Genetic Clinics Activity in France from 1994 to 1997: A Survey on 801 Patients

Cited by 14 publications

References 27 publications

Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families

Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families

Genetic counselling for familial breast and ovarian cancer in Ontario

BRCA Patients and Clinical Collectives

Contact Info

Product

Resources

About